USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
Collaborations with Innovative Platform Developers will Drive Growth Potential
17-Jul-2023
Global
Market Research
PED8-01-00-00-00
TEMP_2023_8
This research service overviews the global ADC market and provides a 6-year revenue forecast from 2023 to 2028. An ADC comprises multiple components such as the antibody, conjugation chemistry, linker, and payload. Many companies are working on each component while others only develop ADCs, which makes the market highly competitive. The development of targeted delivery vehicles over standard antibodies is improving the performance of these drugs and expanding their potential for treating new cancers. New technologies are trying to address drawbacks of existing ADC technology, such as poor stability, leading to poor tolerability, efficacy, and a narrow therapeutic index and challenging ADC manufacturing.
Frost & Sullivan’s analysis shows that small and mid-sized enterprises that rely on contract development and manufacturing organizations (CDMOs)/contract research organizations (CROs) for initial drug development create novel antibody therapeutic technologies. Many antibody developers have been decreasing in-house R&D efforts and increasing in-licensing or acquiring therapeutic antibody product lines to strengthen their pipelines. All major CDMOs are stepping up with new investments to support the next generation of ADC, making the segment more competitive. Biopharmaceutical companies are focusing on ADCs to reap the benefits of target specificity for selective tumor antigens. Developers are using robust approaches to improve payloads’ potency as ADCs reflect the success rate in the last two years with seven approvals.
Other information included in the report consists of the following:
• Market trends
• Leading disruptors
• Marketed and pipeline ADC that will drive growth in hematological and solid tumors
• Growth opportunities emerging from this space that stakeholders can leverage
Author: Surbhi Gupta
Why Is It Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the ADC Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Scope of Analysis
ADC Market Highlights
Growth Opportunities: The ADC Market
Growth Drivers
Growth Restraints
Drug Conjugates’ History, Progress, and Research Stages
ADC Market Trends
ADC Technology Evolution
Precision Oncology Approaches for ADCs
Biomarker Application Across the Cancer Continuum
Life Cycle Management Strategies
ADC Deals and Investment Outlook
Notable ADC Partnerships and Collaborations, 2022
Notable ADC Partnerships and Collaborations, 2022 (continued)
Notable ADC Partnerships and Collaborations, 2022 and 2023
Approved ADCs: Hematological Cancer
Approved ADCs: Solid Tumors
Late-stage ADCs to Watch
Forecast Assumptions
Growth Metrics
Revenue Forecast
Revenue Forecast Analysis: Solid Tumors (Launched)
Revenue Forecast Analysis: Solid Tumors (Launched) (continued)
Revenue Forecast Analysis: Solid Tumors (Launched) (continued)
Revenue Forecast Analysis: Solid Tumors (Pipeline)
Revenue Forecast Analysis: Hematological Cancer (Launched)
Revenue Forecast Analysis: Hematological Cancer (Launched) (continued)
Revenue Forecast Analysis: Hematological Cancer (Late-stage Pipeline)
Tubulis: Broad Spectrum of Technology Platforms
LCB: Conjugation Technology Platforms
Synaffix (Lonza): End-to-end ADC Services
WuXi Biologics: ADC CRDMO
Mersana Therapeutics: Late-stage ADC Pipeline and Platform
Iksuda: A Toolbox Approach for ADC Development
Growth Opportunity 1: ADC Combination Therapies for Precision Chemotherapeutics
Growth Opportunity 1: ADC Combination Therapies for Precision Chemotherapeutics (continued)
Growth Opportunity 2: Strategic Partnerships between CDMOs and Early-stage Platform and ADC Developers
Growth Opportunity 2: Strategic Partnerships between CDMOs and Early-stage Platform and ADC Developers (continued)
Growth Opportunity 3: Novel Linkers and Conjugation Chemistries
Growth Opportunity 3: Novel Linkers and Conjugation Chemistries (continued)
List of Exhibits
Legal Disclaimer
List of Figures
- ADCs: Growth Drivers, Global, 2023-2028
- ADCs: Growth Restraints, Global, 2023-2028
- ADCs: Growth Metrics, Global, 2022
- ADCs: Revenue Forecast, Global, 2021-2028
Speak directly with our analytics experts for tailored recommendations.
Recent related Healthcare research
15 Sep 2026 | Global | Market Research
Vendor Profiles: Advanced Wound Care Management Market, Global, 2025
The wound care market is being transformed by advanced technologies and evolving care models that focus on improving patient outcomes and reducing healthcare costs. Innovations such as smart sensor-embedded dressings, artificial intelligence (AI)-based wound imaging systems, enhanced negative pressu...
11 Sep 2026 | Global | Frost Radar
Frost Radar™: Pharmaceutical Commercialization Solutions and Services, 2026
Pharmaceutical commercialization is a multidimensional concept in the successful launch and distribution of a drug. The process includes the development of a pricing strategy that reflects the drug’s value, negotiation with payers to ensure drug cost coverage, regulatory compliance, and the generati...
07 Sep 2026 | Global | Technology Research
Synthetic Antibodies and AI-Optimized Immunotherapies
Artificial intelligence is becoming increasingly relevant to antibody discovery and immunotherapy development, supporting target identification, de novo antibody design, antibody engineering, clinical intelligence, and bioprocessing. Advances in generative AI, protein language models, diffusion mode...
28 Aug 2026 | Global | Technology Research
Innovations and Growth Opportunities in Advanced Medical Devices, Artificial Intelligence Solutions, Digital Solutions, and Medical Imaging Solutions
The latest issue of Advanced MedTech Technology Opportunity Engine (TOE) spotlights a diverse slate of innovations across advanced medical devices, artificial intelligence solutions, digital solutions, and medical imaging solutions.The issue features advanced medical devices such as active bioelectr...
27 Aug 2026 | Global | Frost Radar
Frost Radar: AI-Powered Molecular Diagnostics, 2026
AI-powered molecular diagnostics is an emerging and moderately fragmented industry that includes molecular diagnostics companies, precision medicine platforms, sequencing specialists, AI-driven analytics providers, and disease-focused biotechnology companies. No single company has dominated, present...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
| Deliverable Type | Market Research |
|---|---|
| Author | Surbhi Gupta |
| Industries | Healthcare |
| No Index | No |
| Is Prebook | No |
| Keyword 1 | Antibody Drug Conjugate |
| Keyword 2 | Adc Drug |
| Keyword 3 | Drug Conjugate |
| List of Charts and Figures | ADCs: Growth Drivers, Global, 2023-2028~ ADCs: Growth Restraints, Global, 2023-2028~ ADCs: Growth Metrics, Global, 2022~ ADCs: Revenue Forecast, Global, 2021-2028~ |
| Podcast | No |
| WIP Number | PED8-01-00-00-00 |
Global Antibody Drug Conjugate (ADC) Growth Opportunities, Forecast to 2028
$2,450.00
Special Price $1,837.50 save 25 %